Risks and Clinical Predictors of Hepatocellular Carcinoma in Chinese Populations: A Real-World Study of 10,359 Patients in Six Medical Centers

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Hayashi S, Nagaoka K, Tanaka Y. Blood-based biomarkers in hepatitis B virus-related hepatocellular carcinoma, including the viral genome and glycosylated proteins. Int J Mol Sci. 2021;22(20). doi:10.3390/ijms222011051
   Web of Science ®Google Scholar
• Wang Y, Tong Y, Zhang Z, et al. ViMIC: a database of human disease-related virus mutations, integration sites and cis-effects. Nucleic Acids Res. 2022;50(D1):D918–D927. doi:10.1093/nar/gkab779
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Yang JD, Addissie BD, Mara KC, et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev. 2019;28(3):531–538. doi:10.1158/1055-9965.EPI-18-0281
   PubMed Web of Science ®Google Scholar
• Trevisan franca de lima L, Broszczak D, Zhang X, Bridle K, Crawford D, Punyadeera C. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188451. doi:10.1016/j.bbcan.2020.188451
   PubMed Web of Science ®Google Scholar
• Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020;7(3):308–319. doi:10.1016/j.gendis.2020.01.014
   PubMed Web of Science ®Google Scholar
• Liu X, Lu J, Zhang G, et al. A machine learning approach yields a multiparameter prognostic marker in liver cancer. Cancer Immunol Res. 2021;9(3):337–347. doi:10.1158/2326-6066.CIR-20-0616
   PubMed Web of Science ®Google Scholar
• Tayob N, Christie I, Richardson P, et al. Validation of the hepatocellular carcinoma early detection screening (hes) algorithm in a cohort of veterans with cirrhosis. Clin Gastroenterol Hepatol. 2019;17(9):1886–1893 e1885. doi:10.1016/j.cgh.2018.12.005
   PubMed Web of Science ®Google Scholar
• Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol. 2016;14(6):875–886 e876. doi:10.1016/j.cgh.2015.12.042
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23(1):144–153. doi:10.1158/1055-9965.EPI-13-0870
   PubMed Web of Science ®Google Scholar
• Best J, Bechmann LP, Sowa JP, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2020;18(3):728–735 e724. doi:10.1016/j.cgh.2019.11.012
   PubMed Web of Science ®Google Scholar
• Huang C, Fang M, Xiao X, et al. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study. Liver Int. 2022;42(1):210–223. doi:10.1111/liv.15082
   PubMed Web of Science ®Google Scholar
• Wang Q, Chen Q, Zhang X, et al. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2019;25(36):5515–5529. doi:10.3748/wjg.v25.i36.5515
   PubMed Web of Science ®Google Scholar
• Alexander M, Loomis AK, van der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 2019;17(1):95. doi:10.1186/s12916-019-1321-x
   PubMed Web of Science ®Google Scholar
• Chinese Society of Infectious Diseases CMA, Chinese Society of Hepatology CMA. 慢性乙型肝炎防治指南(2019版) [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. Zhonghua Gan Zang Bing Za Zhi. 2019;27(12):938–961. Chinese. doi:10.3760/cma.j.issn.1007-3418.2019.12.007
   PubMedGoogle Scholar
• Hashem S, ElHefnawi M, Habashy S, et al. Machine learning prediction models for diagnosing hepatocellular carcinoma with HCV-related chronic liver disease. Comput Methods Programs Biomed. 2020;196:105551. doi:10.1016/j.cmpb.2020.105551
   PubMed Web of Science ®Google Scholar
• Ghosh S, Bhowmik S, Majumdar S, et al. The exosome encapsulated microRNAs as circulating diagnostic marker for hepatocellular carcinoma with low alpha-fetoprotein. Int, J, Cancer. 2020;147(10):2934–2947. doi:10.1002/ijc.33111
   PubMed Web of Science ®Google Scholar
• Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49(10):1109–1113. doi:10.1111/hepr.13411
   PubMed Web of Science ®Google Scholar
• Zhao T, Jia L, Li J, et al. Heterogeneities of site-specific N-Glycosylation in HCC tumors with low and high AFP concentrations. Front Oncol. 2020;10:496. doi:10.3389/fonc.2020.00496
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang Y, Yang N, et al. Evaluation of the combined application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: a Meta-analysis. Biomed Res Int. 2020;2020:5087643. doi:10.1155/2020/5087643
   PubMed Web of Science ®Google Scholar
• Chalasani NP, Ramasubramanian TS, Bhattacharya A, et al. A novel blood-based panel of methylated DNA and protein markers for detection of early-stage hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2021;19(12):2597–2605 e2594. doi:10.1016/j.cgh.2020.08.065
   PubMed Web of Science ®Google Scholar
• Cheng J, Wang W, Zhang Y, et al. Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. PLoS One. 2014;9:1.
   Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T. Highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein: a new tool for the management of hepatocellular carcinoma. Oncology. 2011;81(Suppl 1):61–65. doi:10.1159/000333263
   PubMedGoogle Scholar
• Wang NY, Wang C, Li W, et al. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J Cancer Prev. 2014;15(4):1539–1544. doi:10.7314/APJCP.2014.15.4.1539
   PubMedGoogle Scholar
• Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellular carcinoma serum markers. Semin Oncol. 2012;39(4):410–433. doi:10.1053/j.seminoncol.2012.05.001
   PubMed Web of Science ®Google Scholar
• Nouso K, Kobayashi Y, Nakamura S, et al. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol. 2011;26(7):1195–1200. doi:10.1111/j.1440-1746.2011.06720.x
   PubMed Web of Science ®Google Scholar
• Ji J, Liu L, Jiang F, et al. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: a multi-center study in China. J Clin Lab Anal. 2021;35(11):e24013. doi:10.1002/jcla.24013
   PubMed Web of Science ®Google Scholar
• Ji J, Wang H, Li Y, et al. Diagnostic evaluation of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in china: a large-scale, multicentre study. PLoS One. 2016;11(4):e0153227. doi:10.1371/journal.pone.0153227
   PubMed Web of Science ®Google Scholar
• Singal AG, Tayob N, Mehta A, et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 2022;75(3):541–549. doi:10.1002/hep.32185
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2015;21(37):10573–10583. doi:10.3748/wjg.v21.i37.10573
   PubMed Web of Science ®Google Scholar
• Singal AG, Hoshida Y, Pinato DJ, et al. International Liver Cancer Association (ILCA) white paper on biomarker development for hepatocellular carcinoma. Gastroenterology. 2021;160(7):2572–2584. doi:10.1053/j.gastro.2021.01.233
   PubMed Web of Science ®Google Scholar
• Huang C, Fang M, Feng H, et al. N-glycan fingerprint predicts alpha-fetoprotein negative hepatocellular carcinoma: a large-scale multicenter study. Int, J, Cancer. 2021;149(3):717–727. doi:10.1002/ijc.33564
   PubMed Web of Science ®Google Scholar
• Huang C, Liu L, Wang H, et al. Serum N-glycan fingerprint nomogram predicts liver fibrosis: a multicenter study. Clin Chem Lab Med. 2021;59(6):1087–1097. doi:10.1515/cclm-2020-1588
   PubMed Web of Science ®Google Scholar
• Huang C, Xu X, Wang M, et al. Serum N-glycan fingerprint helps to discriminate intrahepatic cholangiocarcinoma from hepatocellular carcinoma. Electrophoresis. 2021;42(11):1187–1195. doi:10.1002/elps.202000392
   PubMed Web of Science ®Google Scholar
• Liu W, Li X, Zheng W, Yao R, Zheng J. Preoperative evaluation of the degree of liver fibrosis based on matter-element analysis using serological indicators in patients with hepatocellular carcinoma. Biosci Trends. 2019;13(1):70–76. doi:10.5582/bst.2018.01311
   PubMed Web of Science ®Google Scholar